title: [IgA nephropathy: what you have need to know in 2005].
abstract: Although considered as a benign glomerulopathy, IgA nephropathy (IgAN) is now a well-known cause of end-stage renal disease (ESRD). Fifty percent of people suffering from IgAN developp renal insufficiency and 20 to 30% may reach ESRD after 20 to 25 years of evolution. ACEI is indicated to obtain a thigh control of blood pressure and to reduce proteinuria. Corticosteroids alone or in association with immunosuppressants are indicated for agressive, proliferative form of the disease or when there is an unfavorable outcome despite symptomatic treatment.
authors.affiliation: Service de Néphrologie et Hypertension, Dresse Solange Moll, Institut de Pathologie. anne.cherpillod@chuv-hospvd.ch
authors.forename: A
authors.initials: A
authors.lastname: Cherpillod
authors.forename: S
authors.initials: S
authors.lastname: Moll
authors.forename: J P
authors.initials: JP
authors.lastname: Venetz
authors.forename: G
authors.initials: G
authors.lastname: Halabi
mesh_terms: D005922:Glomerulonephritis, IGA / Q000175:diagnosis* / Q000188:drug therapy* / Q000453:epidemiology; D006801:Humans; D011379:Prognosis